Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2019

View Archived Issues

TNFR2 is yang to TNFR1's yin

IL-13Rlalpha2 as a therapeutic target in inflammatory bowel disease

Adropin is correlated with erectile dysfunction in coronary artery disease patients

Fast skeletal muscle troponin activators can counter skeletal muscle fatigue

Triple kinase inhibitor IBL-302 shows promising activity in preclinical models of neuroblastoma

New sialyltransferase inhibitors synthesized at Radboud Universiteit Nijmegen

InnoCare Pharma patents indoleamine 2,3-dioxygenase 1 inhibitors

Initiator Pharma provides an update on IPED-2015 and IP-2018 development

Anti-LAG-3 fully human innovative antibody LBL-007 receives clinical approval

Decrease in tumor biomarkers seen in AIVITA's phase II study in patients with glioblastoma

Gritstone Oncology initiates phase I/II study of neoantigen-based therapeutic cancer vaccine

Positive topline results presented from ELIPSE HoFH phase III study of evinacumab

Themis Bioscience recruiting participants in phase I study of MV-ZIKA-RSP vaccine

H3R inverse agonist LML-134 demonstrates rapid brain penetration and fast kinetic profile

Pharmacokinetics and safety data presented from phase I study of EA-230

Sunshine Lake Pharma discovers sodium/glucose cotransporter 1 inhibitors

New dopamine D3 receptor antagonists synthesized at Shionogi

Cadila Healthcare identifies bacterial DNA topoisomerase II inhibitors

FDA approves new drug combination for highly drug-resistant tuberculosis

Rozlytrek approved by FDA or two new cancer indications

CARB-X awards funding to IBT to expand development of its IBT-V02 vaccine

Helmholtz Zentrum Munchen, Phio to identify new targets based on sd-rxRNA platform

CytoDyn provides update on its HIV dose-escalating monotherapy trial of leronlimab

Soligenix awarded grant to evaluate SGX-942 in pediatric indications

In dopamine D1 receptor combo, ghrelin is resurrected as Alzheimer's target

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...